open access

Vol 9, No 3 (2004)
Original papers
Published online: 2004-01-01
Submitted: 2004-02-13
Get Citation

IUMPA–2: release of medroxyprogesterone acetate from the intrauterine system in the treatment of endometrial hyperplasia relative to the patient's body mass index (BMI)

Andrzej J. Kowalski, Jakub Welfel, Jacek Suzin
DOI: 10.1016/S1507-1367(04)71012-3
·
Rep Pract Oncol Radiother 2004;9(3):73-75.

open access

Vol 9, No 3 (2004)
Original papers
Published online: 2004-01-01
Submitted: 2004-02-13

Abstract

Aim

First, to develop a system of an intrauterine diaphragm with medroxyprogesterone acetate in the treatment of endometrial hyperplasia. Second, to check the distribution of this drug depending on the patient's BMI.

Materials and methods

The study comprised a group of 20 postmenopausal patients with histologically diagnosed simple hyperplasia treated with IUMPA-2 using endoscopic techniques (hysteroscopic targeted endometrial biopsy), histological methods (bioptate assessment) and ultrasound techniques (treatment volume and endometrial measurements).

Results

In all patients investigated the rate of medroxyprogesterone acetate release increased with BMI, which had an effect on the treatment time ranging between 35 and 14 days, respectively.

Conclusions

1) The BMI affects the rate of medroxyprogesterone acetate release from IUMPA-2. 2) In patients with a high BMI double (sequentially) application of a diaphragm should be considered.

Abstract

Aim

First, to develop a system of an intrauterine diaphragm with medroxyprogesterone acetate in the treatment of endometrial hyperplasia. Second, to check the distribution of this drug depending on the patient's BMI.

Materials and methods

The study comprised a group of 20 postmenopausal patients with histologically diagnosed simple hyperplasia treated with IUMPA-2 using endoscopic techniques (hysteroscopic targeted endometrial biopsy), histological methods (bioptate assessment) and ultrasound techniques (treatment volume and endometrial measurements).

Results

In all patients investigated the rate of medroxyprogesterone acetate release increased with BMI, which had an effect on the treatment time ranging between 35 and 14 days, respectively.

Conclusions

1) The BMI affects the rate of medroxyprogesterone acetate release from IUMPA-2. 2) In patients with a high BMI double (sequentially) application of a diaphragm should be considered.

Get Citation

Keywords

IUMPA; hormone treatment; endometrial hyperplasia

About this article
Title

IUMPA–2: release of medroxyprogesterone acetate from the intrauterine system in the treatment of endometrial hyperplasia relative to the patient's body mass index (BMI)

Journal

Reports of Practical Oncology and Radiotherapy

Issue

Vol 9, No 3 (2004)

Pages

73-75

Published online

2004-01-01

DOI

10.1016/S1507-1367(04)71012-3

Bibliographic record

Rep Pract Oncol Radiother 2004;9(3):73-75.

Keywords

IUMPA
hormone treatment
endometrial hyperplasia

Authors

Andrzej J. Kowalski
Jakub Welfel
Jacek Suzin

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk, Poland
tel.:+48 58 320 94 94, fax:+48 58 320 94 60, e-mail: journals@viamedica.pl